Table 5.
Factors related to circulating sex hormone–binding globulin concentration in men
| Men | ||||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||
| Factors | β (95% CI) | P | β (95% CI) | P | β (95% CI) | P |
| Age, y | –0.03 (–0.13 to 0.075) | .58 | –0.024 (–0.14 to 0.086) | .66 | –0.026 (–0.15 to 0.10) | .69 |
| Whole-body fat mass, kg | 0.004 (–0.07 to 0.08 | .91 | 0.003 (–0.072 to 0.078) | .09 | 0.011 (–0.09 to 0.11) | .83 |
| Whole-body lean mass, kg | -0.21 (–0.32 to –0.10) | < .001 | –0.18 (–0.29 to –0.069) | .002 | –0.20 (–0.33 to –0.70) | .003 |
| HIV– serostatus | Reference | – | Reference | – | Reference | |
| HIV+ serostatus | ||||||
| HIV RNA (≤ 400 copies/mL) | 0.42 (–1.00 to 1.85) | .56 | 0.49 (–0.92 to 1.91) | .49 | 0.22 (–1.39 to 1.83) | .79 |
| HIV RNA (> 400 copies/mL) | 2.02 (–0.42 to 4.47) | .11 | 1.87 (–0.54 to 4.28) | .13 | 2.26 (–0.65 to 5.17) | .13 |
| HCV RNA (> 15 IU/mL) | 2.30 (0.86 to 3.74) | .002 | 2.22 (0.81 to 3.64) | .002 | 2.52 (0.88 to 4.16) | .003 |
| Diabetes | 0.77 (–1.39 to 2.94) | .48 | 0.54 (–1.61 to 2.70) | .62 | –0.17 (–3.66 to 3.32) | .93 |
| AST, U/L | – | – | 0.017 (–0.009 to 0.044) | .19 | – | – |
| ALT, U/L | – | – | 0.0031 (–0.024 to 0.031) | .82 | – | – |
| Liver stiffness, kPa | – | – | – | – | 0.14 (0.022 to 0.27) | .021 |
| Liver disease | 0.73 (–0.59 to 2.06) | .28 | – | – | – | – |
HCV RNA (undetectable ≤ 15 IU/mL = reference, detectable > 15 IU/mL), HCV RNA (undetectable ≤ 15 IU/mL = reference, detectable > 15 IU/mL); liver disease: based on FibroScan, fibrosis was ≥ 9.3 kPa.
Outcome: SHBG (per 10 nmol/L); multivariate linear regression; unadjusted.
Model 1: adjusted for age, sex whole-body lean mass, whole-body total fat, HIV RNA ((HIV seronegative = reference, ≤ 400 copies/mL, > 400 copies/mL, HCV RNA (≤ 15 IU/mL = reference, > 15 IU/mL), diabetes, liver disease: based on FibroScan, fibrosis was ≥ 9.3 kPa.
Model 2: adjusted for age, sex whole-body lean mass, whole-body total fat, HIV RNA ((HIV seronegative = reference, ≤ 400 copies/mL, > 400 copies/mL, HCV RNA (≤ 15 IU/mL = reference, > 15 IU/mL), diabetes, AST, and ALT.
Model 3: adjusted for age, sex whole-body lean mass, whole-body total fat, HIV RNA ((HIV seronegative = reference, ≤ 400 copies/mL, > 400 copies/mL, HCV RNA (≤ 15 IU/mL = reference, > 15 IU/mL), diabetes, and liver stiffness continuous.
Abbreviations: β, regression coefficient; ALT, alanine transaminase; AST, aspartate transaminase; HCV, hepatitis C virus; SHBG, sex hormone–binding globulin.